Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.52 |
| ▸ | GSK3B | P49841 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13288786 | 0.95 | CDK2 (0.49) | CDK2GSK3BKDM4EPDE2APDE10A | |
| SCHEMBL13119436 | 0.90 | CDK2 (0.66) | CDK2GSK3B | |
| SCHEMBL13288769 | 0.88 | CDK2 (0.55) | CDK2GSK3BPDE2APDE10A | |
| SCHEMBL13288668 | 0.88 | CDK2 (0.55) | CDK2GSK3BPDE2APDE10A | |
| SCHEMBL13288768 | 0.87 | CDK2 (0.54) | CDK2GSK3B | |
| SCHEMBL13288782 | 0.87 | CDK2 (0.54) | CDK2GSK3BKDM4E | |
| SCHEMBL13288882 | 0.87 | CDK2 (0.54) | CDK2GSK3BPDE2APDE10A | |
| SCHEMBL13119301 | 0.85 | CDK2 (0.62) | CDK2GSK3B | |
| SCHEMBL13289148 | 0.85 | CDK2 (0.52) | CDK2GSK3BPDE2APDE10AKLKB1 | |
| SCHEMBL13288866 | 0.84 | CDK2 (0.59) | CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |